Anticoagulation Therapy

Introduction to Anticoagulation

Anticoagulants have greater activity against Factor Xa than thrombin, with a 4:1 ratio of Factor Xa to thrombin activity, reduced binding to plasma proteins resulting in more predictable anticoagulant effect, and a longer half-life than unfractionated heparin, as noted by the American Heart Association 1
The American College of Cardiology recommends anticoagulants due to their lower incidence of heparin-induced thrombocytopenia 1

In patients with multiple trauma, anticoagulants reduced thrombosis compared to low-dose heparin (31% vs 44%) 2
Anticoagulants can be used in combination with thrombolytic therapy for acute coronary syndromes, as recommended by the American Heart Association 3
Low molecular weight heparin (LMWH) reduced venous thrombosis compared to unfractionated heparin (15.9% vs 21.7%) in a meta-analysis 2
Anticoagulation therapy is crucial for managing deep vein thrombosis (DVT), with various regimens and guidelines available for different patient populations, as recommended by the American Heart Association, the American College of Chest Physicians, and the National Comprehensive Cancer Network 4, 5, 6, 7

Patients on anticoagulants should be monitored for clinical signs of bleeding or thrombosis, with routine anti-factor Xa level monitoring not recommended, as suggested by the American Society of Hematology 8
Renal function should be monitored at least yearly in stable patients, and more frequently in high-risk patients, according to the International Society on Thrombosis and Haemostasis 9
Patients should receive adequate counseling when anticoagulants are prescribed, including information on treatment indication, dosing schedule, and signs of bleeding to watch for, as recommended by the International Society on Thrombosis and Haemostasis 9

Weight-based dosing is preferred over fixed-dose regimens, according to the National Comprehensive Cancer Network 10
The standard dosing for enoxaparin is 1 mg/kg twice daily or 1.5 mg/kg once daily for treatment, as recommended by the Mayo Clinic 11

Prophylactic dosing regimens are as follows:

Population	Prophylactic Dose
Standard prophylaxis	40 mg subcutaneously once daily [12, 13, 5]
Severe renal insufficiency (CrCl <30 mL/min)	30 mg subcutaneously once daily [14, 5]
High-risk surgical patients	30 mg subcutaneously twice daily [15, 16]
Class III obesity (BMI >40)	40 mg twice daily or 0.5 mg/kg twice daily [14, 15]

For patients with severe renal impairment (CrCl <30 mL/min), consideration of unfractionated heparin as an alternative to enoxaparin is recommended 17
For patients with severe renal insufficiency (CrCl <30 mL/min), the dose of enoxaparin should be reduced to 1 mg/kg once daily, as recommended by the American Heart Association and the American College of Chest Physicians 18, 19, 20

Morbidly obese patients (BMI >40 kg/m²) may require weight-based dosing, as recommended by the National Comprehensive Cancer Network 5
Pregnant women may require dose adjustments based on anti-Xa levels, but there is no clear clinical benefit demonstrated, and the American Society of Hematology recommends against routine monitoring, with a strength of evidence of IIb (low) 21
Pediatric patients require age-specific dosing, with target ranges of 0.5-1.0 IU/mL, and dosing as follows:
Elderly patients (>65 years) with renal impairment or other risk factors may require a reduced initial dose of 30 mg every 12 hours, according to the World Journal of Emergency Surgery guidelines 23

Routine monitoring of anti-Xa levels is not recommended for most patients, but may be considered in patients with severe renal impairment, morbidly obese patients, pregnant patients, or pediatric patients, as recommended by the American Society of Hematology 20, 24
Anti-Xa levels should be measured 4 hours after LMWH administration, with target levels of 0.6-1.0 units/mL for twice-daily enoxaparin or nadroparin, and 1.0 units/mL for once-daily enoxaparin 20
Baseline laboratory testing should include complete blood count, renal and hepatic function panel, aPTT, and PT/INR, with follow-up monitoring including hemoglobin, hematocrit, and platelet count at least every 2-3 days for the first 14 days and every 2 weeks thereafter, as recommended by the National Comprehensive Cancer Network 4, 25
Platelet monitoring is recommended during treatment due to the risk of heparin-induced thrombocytopenia, as suggested by the American Society of Hematology, with a strength of evidence of IIb (low) 26

Aspirin loading dose of 150-300 mg orally (or 75-250 mg IV) followed by maintenance dose of 75-100 mg daily long-term is recommended by the European Society of Cardiology 27
Dual Antiplatelet Therapy (DAPT) with a potent P2Y12 inhibitor (prasugrel or ticagrelor) or clopidogrel plus aspirin for 12 months is recommended in patients with multivessel disease, as suggested by the European Society of Cardiology 27